A review of topically administered mini- tablets for drug delivery to the anterior segment of the eye

被引:18
作者
Moosa, Raeesa M. [1 ]
Choonara, Yahya E. [1 ]
du Toit, Lisa C. [1 ]
Kumar, Pradeep [1 ]
Carmichael, Trevor [2 ]
Tomar, Lomas Kumar [1 ]
Tyagi, Charu [1 ]
Pillay, Viness [1 ]
机构
[1] Univ Witwatersrand, Fac Hlth Sci, Dept Pharm & Pharmacol, ZA-2193 Johannesburg, South Africa
[2] Univ Witwatersrand, Fac Hlth Sci, Dept Neurosci, Div Ophthalmol, ZA-2193 Johannesburg, South Africa
关键词
anterior segment of the eye; drug delivery; mini-tablets; rapidly dissolving tablet; IN-VIVO EVALUATION; CHITOSAN NANOPARTICLES; CONTAINING MINITABLETS; MUCOADHESIVE POLYMERS; SYSTEMIC ABSORPTION; OPHTHALMIC INSERTS; CONTROLLED-RELEASE; VITRO EVALUATION; OCULAR DELIVERY; CONTACT-LENSES;
D O I
10.1111/jphp.12131
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
ObjectivesThe human eye is a unique and intricate structure which has made drug delivery to the eye a formidable undertaking. Anterior-segment eye diseases are ubiquitous, especially among elderly patients, and conventional eye drops, although a first-choice dosage form, are not always an efficient treatment option. The development of novel drug delivery systems for improved treatment is therefore imperative. Key findingsIn an attempt to circumvent the obstacles presented by the structure of the eye, advanced systems such as ocular mini-tablets have been developed. In this review, a concerted effort has been made to provide a detailed overview of topically administered ocular mini-tablets and other solid devices for drug delivery to the anterior segment of the eye. These mini-tablets have been shown in vitro and in vivo to have significant advantages in comparison with liquid preparations. This is a step toward attaining better patient convenience and compliance, which are critical factors. SummarySolid ophthalmic dosage forms have several advantages that can contribute to assisting with patient compliance and, ultimately, effective disease treatment. In addition to the challenges associated with topical ocular drug delivery, the shortcomings of conventional eye drops, advantages of mini-tablets, and improvements to date to these systems are discussed. The requirement for further advancements in the ocular field is also emphasized.
引用
收藏
页码:490 / 506
页数:17
相关论文
共 113 条
[1]  
Ahmed I., 2003, DRUGS PHARM SCI, V130, P335, DOI [10.1201/9780203912072.ch11, DOI 10.1201/9780203912072.CH11]
[2]   Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow [J].
Ali, Maryarn ;
Horikawa, Shin ;
Venkatesh, Siddarth ;
Saha, Jishnu ;
Hong, Jong Wook ;
Byrne, Mark E. .
JOURNAL OF CONTROLLED RELEASE, 2007, 124 (03) :154-162
[3]  
Andrés-Guerrero V., 2008, Arch Soc Esp Oftalmol, V83, P683
[4]   Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response [J].
Anumolu, SivaNaga S. ;
Singh, Yashveer ;
Gao, Dayuan ;
Stein, Stanley ;
Sinko, Patrick J. .
JOURNAL OF CONTROLLED RELEASE, 2009, 137 (02) :152-159
[5]  
Arulkumaran K.S.G., 2010, INT J PHARM PHARM SC, V2, P1
[6]  
Barar Jaleh, 2009, J Ophthalmic Vis Res, V4, P238
[7]  
Bawa R., 1993, OPHTHALMIC DRUG DELI, P223
[8]   Mucoadhesive Microdiscs Engineered for Ophthalmic Drug Delivery: Effect of Particle Geometry and Formulation on Preocular Residence Time [J].
Bin Choy, Young ;
Park, Jung-Hwan ;
McCarey, Bernard E. ;
Edelhauser, Henry F. ;
Prausnitz, Mark R. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2008, 49 (11) :4808-4815
[9]   In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops [J].
Bozdag, S. ;
Weyenberg, W. ;
Adriaens, E. ;
Dhondt, M. M. M. ;
Vergote, V. ;
Vervaet, C. ;
De Prijck, K. ;
Nelis, H. J. ;
De Spiegeleer, B. ;
Ludwig, A. ;
Remon, J. P. .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2010, 36 (11) :1259-1270
[10]   Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability [J].
Callens, C ;
Pringels, E ;
Remon, JP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 250 (02) :415-422